<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A738CC33-761D-4E54-A93E-2A9B2B5049BA"><gtr:id>A738CC33-761D-4E54-A93E-2A9B2B5049BA</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Allan</gtr:otherNames><gtr:surname>Cairns</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802416"><gtr:id>9D779508-C45F-4849-BA6E-0B83DFF491ED</gtr:id><gtr:title>Novel statistical methods for the design and analysis of proteomic experiments for biomarker discovery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802416</gtr:grantReference><gtr:abstractText>There is an urgent need for new medical tests which can be used to diagnose a disease or to determine how severe a disease is. Such tests can result in earlier and better treatment, increase the chance of recovery and help select the best treatment. A lot of medical research is looking in body fluids such as blood and urine to find proteins (one of the key type of molecules which make up cells and tissues of the body) which could act as markers of disease and be measured in a simple test. Such research uses quite complex technologies and produces very large amounts of data and the purpose of this proposal is to develop the best methods of statistical analysis for this type of data. This is essential so that we reach the right conclusions about whether a marker is a good or bad one.</gtr:abstractText><gtr:technicalSummary>Aims: 
To develop novel statistical methods for the experimental design, monitoring and analysis of proteomic profiling experiments (PPE) in biomarker discovery research.

Specific objectives: 
1) To develop approaches for statistical experimental design to perform PPE efficiently.
2) To extend sample size calculation techniques to experimental designs for the discovery of therapeutic and prognostic biomarkers.
3) To adapt quality control methodology to be applied to 2-dimensional difference in gel electrophoresis (2D DIGE) and liquid chromatography and mass spectrometry (MS) tagging (iTRAQ) and labelling (SILAC) techniques.
4) To construct flexible statistical models for the analysis of PPE which include elements of pre-processing and salient experimental and differential expression effects.
5) To compare and contrast both Bayesian and classical inference techniques as appropriate and to contrast and compare results.

Methodology: 
These objectives will be fulfilled by applying and developing modern statistical techniques of design and analysis to maximise the potential of PPE. This will involve the use of methods in statistical experimental design such as blocking and cycling. In conjunction with this methods for sample size calculations for PPE will be constructed for designs which can be used in the detection of therapeutic and diagnostic biomarkers, correctly allowing for issues of multiple testing and variance estimation. Each of these methods will be extended from MS based PPE to 2D DIGE and labelling techniques such as iTRAQ and SILAC. Careful use of the similarities (and dissimilarities) between the technical and biological aspects of these PPE technologies and experimental process will be used to construct statistical models and techniques from an underlying model. Methods of classical and Bayesian inference will be used to answer clinically relevant questions.

Scientific and medical opportunities: 
The effectiveness of costly biomedical research may be maximised by increasing the level of statistical input. This is particularly true at the discovery stage of an investigation. A false positive result can lead to further wasted resources in ultimately negative validation whereas a false negative result could lead to the non-identification of an important biological finding. This is the case in biomarker discovery research where well-designed powerful experiments in conjunction with modern statistical analysis techniques can maximise the potential of such studies and hence deliver clinically useful biomarkers.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>323782</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Institute of Oncology (IEO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Experimental Oncology</gtr:department><gtr:description>IFOM-IEO Bonaldi</gtr:description><gtr:id>D17E401B-EF09-4F7E-834B-50A84D13559E</gtr:id><gtr:impact>Invited presentation by key collaborator (Tiziana Bonaldi) at HUPO meeting 20010 in Sydney. This collaboration is certainly multi-disciplinary bringing together biologists, chemists, bioinformaticians and biostatisticians.</gtr:impact><gtr:outcomeId>H4aKeF3cBCn-1</gtr:outcomeId><gtr:partnerContribution>The exchange of data and expertise in cell biology and mass spectrometry.</gtr:partnerContribution><gtr:piContribution>The development of methods for the analysis of mass spectrometry data from SILAC (stable isotope labelling by amino acids in cell culture) for experiments investigating mechanisms of transcriptional regulation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>A9F55737-3C38-4D88-9E67-7ACF65D066D6</gtr:id><gtr:title>Statistical issues in the design and planning of proteomic profiling experiments.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b75dfb3c06dee46b4a9c493231c0dea"><gtr:id>6b75dfb3c06dee46b4a9c493231c0dea</gtr:id><gtr:otherNames>Cairns DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5675dcb44c9ab</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DB05317-F88E-4A40-BC90-B4FA1242C111</gtr:id><gtr:title>The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.</gtr:title><gtr:parentPublicationTitle>Archives of gynecology and obstetrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c385b70a055ac30433ecf2247695e37a"><gtr:id>c385b70a055ac30433ecf2247695e37a</gtr:id><gtr:otherNames>Vasudev NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0932-0067</gtr:issn><gtr:outcomeId>p9szb75GK9v</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>107BD1AA-4779-4CEB-8AD6-AB3832DDF133</gtr:id><gtr:title>Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9ec0d9b26508eaf993a3909d2823313"><gtr:id>d9ec0d9b26508eaf993a3909d2823313</gtr:id><gtr:otherNames>Young AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14134_14_19996202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56E28DD7-3028-46C2-A6B7-ECB126EDB3F1</gtr:id><gtr:title>Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.</gtr:title><gtr:parentPublicationTitle>Journal of neuro-oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a83923903a5401e181d1b62d8f4b7e0"><gtr:id>1a83923903a5401e181d1b62d8f4b7e0</gtr:id><gtr:otherNames>Rankeillor KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-594X</gtr:issn><gtr:outcomeId>pm_540e166e166aa9577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4513DE6C-AC81-455C-B7A4-361B67E81040</gtr:id><gtr:title>NuMA overexpression in epithelial ovarian cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64de0834f53e7b95ef6b16e75dde33d0"><gtr:id>64de0834f53e7b95ef6b16e75dde33d0</gtr:id><gtr:otherNames>Br?ning-Richardson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14134_24_22719996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BE0F90B-4762-4F98-A076-47193843970C</gtr:id><gtr:title>ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64de0834f53e7b95ef6b16e75dde33d0"><gtr:id>64de0834f53e7b95ef6b16e75dde33d0</gtr:id><gtr:otherNames>Br?ning-Richardson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>Z4kJNhYbHDU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F034C04-21C0-4AFA-A73D-507739043D31</gtr:id><gtr:title>A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89671d6057589cce26f1200cdcf226ee"><gtr:id>89671d6057589cce26f1200cdcf226ee</gtr:id><gtr:otherNames>Thompson D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>M1kUD5ySEDN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A3D6C24-1D91-4318-BCE2-EDDB0CB5B317</gtr:id><gtr:title>miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0caca4a3dc819d8989f073d61cb79fad"><gtr:id>0caca4a3dc819d8989f073d61cb79fad</gtr:id><gtr:otherNames>Mihailovich M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56d97626817f92.18192267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0531F452-9410-4545-867E-5518971AE74B</gtr:id><gtr:title>Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bcbaa39c82b31a9cad4f3a425b4610dd"><gtr:id>bcbaa39c82b31a9cad4f3a425b4610dd</gtr:id><gtr:otherNames>Welberry Smith MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_14134_24_23739232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80368AA3-7B08-47A9-85FE-31B7E7D6CE71</gtr:id><gtr:title>Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6656fc1f279137cef9bdec2326d09ff"><gtr:id>d6656fc1f279137cef9bdec2326d09ff</gtr:id><gtr:otherNames>Wood SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>SGVCMu6YBD3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEBE697D-C499-46C4-8952-691B8D9D67E5</gtr:id><gtr:title>Statistical issues in quality control of proteomic analyses: good experimental design and planning.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b75dfb3c06dee46b4a9c493231c0dea"><gtr:id>6b75dfb3c06dee46b4a9c493231c0dea</gtr:id><gtr:otherNames>Cairns DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>cFV8SKGn858</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>888226FE-4D61-4860-8A4F-AC1461B20EB6</gtr:id><gtr:title>CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/287fa038d0ae5ff6f1bf79b03b9e65c5"><gtr:id>287fa038d0ae5ff6f1bf79b03b9e65c5</gtr:id><gtr:otherNames>Westbrook JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>56d975ddcb01d9.99118137</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CBC1D10-7C08-465B-80F8-B76FFB9C162F</gtr:id><gtr:title>An analysis of the impact of pre-analytical factors on the urine proteome: Sample processing time, temperature, and proteolysis.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fef2a7e2c440e9d8b0c43b9f281f82cb"><gtr:id>fef2a7e2c440e9d8b0c43b9f281f82cb</gtr:id><gtr:otherNames>Hepburn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>58bea74c692e80.25893317</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10DC5AA0-A1B3-4F10-ADB0-3AC65B553C6F</gtr:id><gtr:title>A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.</gtr:title><gtr:parentPublicationTitle>Proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4483f1a162474c6556fc9d1b19223f5"><gtr:id>f4483f1a162474c6556fc9d1b19223f5</gtr:id><gtr:otherNames>Smith MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1615-9853</gtr:issn><gtr:outcomeId>pagkeAUrXhj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9632E9C8-75D7-4352-B7FF-EAF1213E1305</gtr:id><gtr:title>Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age.</gtr:title><gtr:parentPublicationTitle>Proteomics. Clinical applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9328f3f7f6f037ba4b29ee40968c80d7"><gtr:id>9328f3f7f6f037ba4b29ee40968c80d7</gtr:id><gtr:otherNames>Craven RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1862-8346</gtr:issn><gtr:outcomeId>pm_14134_24_23027403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC653F77-B4B9-49CB-8B38-A15C7DD3AADE</gtr:id><gtr:title>Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6636e5adcd163df4068ef99befabda6f"><gtr:id>6636e5adcd163df4068ef99befabda6f</gtr:id><gtr:otherNames>Zougman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn><gtr:outcomeId>pm_14134_24_23021913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EF3A4AE-63BF-4516-B5AA-1093C5E1F814</gtr:id><gtr:title>Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c79ea24fa0bf39b3c4ebfb2454e5726"><gtr:id>0c79ea24fa0bf39b3c4ebfb2454e5726</gtr:id><gtr:otherNames>Collinson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_14134_24_23935036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A6DF81B-D0FB-4F4B-AF06-539CD2F5321D</gtr:id><gtr:title>Biomarkers and response to bevacizumab--response.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c79ea24fa0bf39b3c4ebfb2454e5726"><gtr:id>0c79ea24fa0bf39b3c4ebfb2454e5726</gtr:id><gtr:otherNames>Collinson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5460c11f3e52a3.47052666</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46758A69-C6C7-4B33-B77A-85D0123C657B</gtr:id><gtr:title>Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1952d898e19720fa630579e8fc66da12"><gtr:id>1952d898e19720fa630579e8fc66da12</gtr:id><gtr:otherNames>Nirmalan NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>AhPxYZXVSbw</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802416</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>